Legemiddelbehandling av demens

Dette dokumentet er basert på det profesjonelle dokumentet Demens ved Alzheimers sykdom. Referanselisten for dette dokumentet vises nedenfor.

1. Helsedirektoratet. Demens. Nasjonal faglig retningslinje. Først publisert 16.08.2017. Sist faglig oppdatert 31.10.2022. www.helsedirektoratet.no 
2. McKhann GM, Knopman DS, Chertkow H, et al.. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7(3): 263-9. pmid:21514250 PubMed 
3. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007. PMID: 22265587 PubMed 
4. Rongve A, Årsland D, Graff C. Alzheimers sykdom og genetikk. Tidsskr Nor Legeforen 2013; 133: 1449-52. doi:10.4045/tidsskr.12.0873 DOI 
5. Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Mol Neurodegener. 2022 Nov 8;17(1):72. doi: 10.1186/s13024-022-00574-4. PMID: 36348357; PMCID: PMC9644639.
6. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin. 1907. 64: 146-148.
7. Bowler JV. Modern concept of vascular cognitive impairment. Br Med Bull 2007; 83: 291-305. pmid:17675645 PubMed 
8. Gjøra L, Kjelvik G, Strand BH, et al. Forekomst av demens i Norge. Utgitt av Forlaget aldring og helse 2020. ISBN 978-82-8061-579-4 (PDF). butikk.aldringoghelse.no 
9. Seshadri, S, Beiser, A, Kelly-Hayes, M, Kase, CS, Au, R et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke 2006; 37(2): 345-50. PMID: 16397184 PubMed 
10. Nasjonalt senter for aldring og helse. Demens. Fakta om demens. Siden lest 31.01.2023. www.aldringoghelse.no 
11. Scheltens P, Blennow K, Breteler MM, et al. Alzheimer's disease. Lancet. 2016 Jul 30;388(10043):505-17. Epub 2016 Feb 24.pmid: 26921134 PubMed 
12. Small GW, Siddarth P, Ercoli LM, et al.. Healthy behavior and memory self-reports in young, middle-aged, and older adults. Int Psychogeriatr 2013; 25(6): 981-9. pmid:23425438 PubMed 
13. Hunskår S (red.). Allmennmedisin. S. 419. Gyldendal Norsk Forlag AS. Gyldendal Akademisk, 2003.
14. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789. PMID: 33302541 PubMed 
15. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Biol. 2011 Sep. 3(9):a006189.
16. Haass C, De Strooper B. Review: neurobiology - the presenilins in Alzheimer's disease - proteolysis holds the key. Science 1999; 286: 916-19. PubMed 
17. Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA 2009; 302: 2557-64. Journal of the American Medical Association 
18. Shea YF, Chu LW, Chan AO, et al.. A systematic review of familial Alzheimer's disease: Differences in presentation of clinical features among three mutated genes and potential ethnic differences. J Fomos Med Assoc 2016 Feb; 115(2): 67-75. pmid:26337232 PubMed 
19. Knapskog A-B, Engedal K, Selbæk G, Øksengård A-R. Alzheimers sykdom – diagnostikk og behandling. Tidsskr Nor Legeforen 2021. doi:10.4045/tidsskr.20.0919 DOI 
20. Serrano-Pozo A, Betensky RA, Frosch MP, Hyman BT. Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. Am J Pathol. 2016 Feb;186(2):375-84. doi: 10.1016/j.ajpath.2015.10.010. Epub 2015 Dec 11. PMID: 26687817; PMCID: PMC4729270.
21. Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's Disease: Mechanisms and Therapeutic Strategies. Curr Alzheimer Res. 2018;15(3):283-300. doi: 10.2174/1567205014666170417111859. PMID: 28413986. PubMed 
22. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132. PMID: 29850777; PMCID: PMC6022632.
23. Strac DS, Muck-Seler D, Pivac N. Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review. Psychiatr Danub. 2015 Mar;27(1):14-24. PMID: 25751428 PubMed 
24. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021 Apr 24;397(10284):1577-1590. doi: 10.1016/S0140-6736(20)32205-4. Epub 2021 Mar 2. PMID: 33667416 PubMed 
25. Escott-Price V, Shoai M, Pither R, Williams J, Hardy J. Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. Neurobiol Aging. 2017 Jan;49:214.e7-214.e11. doi: 10.1016/j.neurobiolaging.2016.07.018. Epub 2016 Aug 5. PMID: 27595457. PubMed 
26. Jones EL, Mok K, Hanney M, et al. Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiol Aging 2013; 34(10): 2441.e1-5. pmid:23601808 PubMed 
27. Livingston G, Huntley J, et.al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet 2020 Aug 8;396(10248):413-446. Pmid: 32738937.
28. Marinelli JP, Lohse CM, Fussell WL, et al. Association between hearing loss and development of dementia using formal behavioural audiometric testing within the Mayo Clinic Study of Aging (MCSA): a prospective population-based study. Lancet Healthy Longev 2022. pmid:36410368 PubMed 
29. Coupland CAC, Hill T, Dening T, et al. Anticholinergic Drug Exposure and the Risk of Dementia A Nested Case-Control Study. JAMA Intern Med 2019; 179: 1084-93. pmid:31233095 PubMed 
30. Jayadevappa R, Chhatre S, Malkowicz B, et al. Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer. JAMA Netw Open 2019; 2: e196562. pmid:31268539 PubMed 
31. Sochocka M, Zwolińska K, Leszek J. The Infectious Etiology of Alzheimer's Disease. Curr Neuropharmacol. 2017;15(7):996-1009. PMID: 28294067 PubMed 
32. Athanasopoulos D, Karagiannis G, Tsolaki M. Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. Adv Nutr. 2016 Sep 15;7(5):917-27. doi: 10.3945/an.116.012229. PMID: 27633107 PubMed 
33. Huat TJ, Camats-Perna J, Newcombe EA, et al. Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation. J Mol Biol. 2019 Apr 19;431(9):1843-1868. doi: 10.1016/j.jmb.2019.01.018. Epub 2019 Jan 18. PMID: 30664867 PubMed 
34. Sachdeva A, Chandra M, Choudhary M, et al. Alcohol-Related Dementia and Neurocognitive Impairment: A Review Study. Int J High Risk Behav Addict 2016 ; 5(3): e27976. pmid:27818965 PubMed 
35. Hill NL, Mogle J. Alzheimer's disease risk factors as mediators of subjective memory impairment and objective memory decline: protocol for a construct-level replication analysis. BMC Geriatr 2018; 18(1): 260. pmid:30373526 PubMed 
36. Snowden JS, Thompson JC, Stopford CL, et al. The clinical dianosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; : doi: 10.1093/brain/awr189.
37. Palmer K, Bäckman L, Winblad B, Fratiglioni L. Detection of Alzheimer's disease and dementia in the preclinical phase: population based cohort stud. BMJ 2003; 326: 245-50. British Medical Journal 
38. Pietroboni AM, Scarioni M, Carandini T, et al.. CSF β-amyloid and white matter damage: a new perspective on Alzheimer's disease. J Neurol Neurosurg Psychiatry 2017 ; Epub Oct 20: jnnp-2017-316603. pmid:29054920 PubMed 
39. Øksengård AR, Haakonsen M, Dullerud R, Babovic A, Laake K, Engedal K. Bildediagnostiske metoder ved demensutredning. Tidsskr Nor Lægeforen 2002; 122: 710-4. Tidsskrift for Den norske legeforening 
40. Arevalo-Rodriguez I, Smailagic N, Roque I Figuls M, et al. Mini-Mental State Examination (MMSE) for the detection of Alzheimer`s disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2015 Mar 5;3:CD010783. doi: 10.1002/14651858.CD010783.pub2 DOI 
41. Creavin ST, Wisniewski S, Noel-Storr AH, Trevelyan CM, Hampton T, Rayment D, Thom VM, Nash KJE, Elhamoui H, Milligan R, Patel AS, Tsivos DV, Wing T, Phillips E, Kellman SM, Shackleton HL, Singleton GF, Neale BE, Watton ME, Cullum S. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No.: CD011145. DOI: 10.1002/14651858.CD011145.pub2 DOI 
42. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016 Jan; 79(1): 110-9. pmid:26505746 PubMed 
43. Goldman JS. Genetic testing and counseling in the diagnosis and management of young-onset dementias. Psychiatr Clin North Am 2015; 38(2): 295-308. pmid:25998117 PubMed 
44. National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline [NG97] Published date: June 2018 www.nice.org.uk 
45. Merkuri N, Croy A, Henry S, et al. Comparing and benchmarking national dementia strategies and policies European Dementia Monitor 2017. Alzheimer Europe, 2017
46. Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ 2019; 367: I6930. doi:10.1136/bmj.l6930 DOI 
47. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ 2012; 343: d4065. BMJ (DOI) 
48. Russ TC, Morling JR. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database of Systematic Reviews 2012; 9: CD009132. Cochrane (DOI) 
49. Tricco AC, Soobiah C, Berliner S, et al. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis. CMAJ 2013; 185: 1393-401. pmid:24043661 PubMed 
50. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006; 1: CD005593. Cochrane (DOI) 
51. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97. Annals of Internal Medicine 
52. Soysal P, Isik AT, Stubbs B, et al. Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2016 Jun 3 . pmid:27261502 PubMed 
53. Årsland D, Engedal KA, Nygaard HA, Louhija J, Ulstein I, Holm M. Bruk av kolinesterasehemmere. Tidsskr Nor Lægeforen 2003; 123: 1500-3. PubMed 
54. Landmark K, Reikvam Å. Kolinesterasehemmere mot demens - nyttig i klinisk praksis?. Tidsskr Nor Legeforen 2008; 128: 294-7. tidsskriftet.no 
55. Howard RJ, Juszczak E, Ballard CG, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357: 1382-92. PubMed 
56. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012; 366: 957-9. New England Journal of Medicine 
57. Truong C, Recto C, Lafont C, et al. Effect of Cholinesterase Inhibitors on Mortality in Patients With Dementia: A Systematic Review of Randomized and Nonrandomized Trials. Neurology 2022. PMID: 36096687 PubMed 
58. Qizilbash N. Treatment of Alzheimer's disease. I: Qizilbash N, Schneider L, Chui H, Tariot P, Brodaty H, Kaye J et al. Evidence-based dementia practice. Oxford: Blackwell Science, 2002: 467 - 588.
59. Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2015 ;4:CD001191. PMID: 25858345. PubMed 
60. Statens legemiddelverk. Terapianbefaling. Nytt om legemidler 2003; 26, nr. 6: 10-6.
61. O'Brien JT, Ballard CG. Drugs for Alzheimer's disease (ed). BMJ 2001; 323: 123-4. PubMed 
62. Engedal K, Brækhus A, Gjerstad L. Effekt av legemidler mot demens. Tidsskr Nor Lægeforen 2004; 124: 1641-2. PubMed 
63. Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37(1-2):71-85. doi: 10.1159/000353801 DOI 
64. Winblad B, Poritis N. Memantine in severe dementia: result of the 9M-best study. Int J Geriatr Psychiatry 1999; 14: 135 - 46. PubMed 
65. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD003154. DOI: 10.1002/14651858.CD003154.pub5. DOI 
66. Schneider LS, Dagerman KS, Higgins JPT, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol 2011; e-pub.
67. Lopez OL, Becker JT, Wahed AS. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 600-7. PubMed 
68. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ 2012; 2: e000917. doi:10.1136/bmjopen-2012-000917 DOI 
69. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003120. DOI: 10.1002/14651858.CD003120.pub3. DOI 
70. Vellas B, Coley N, Ousset PJ, et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012. doi:10.1016/S1474-4422(12)70206-5 DOI 
71. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia. JAMA 2008; 300:2253-62. Journal of the American Medical Association 
72. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA 2009; 302: 2663-70. Journal of the American Medical Association 
73. Ruths S, Straand J. Antipsykotiske midler mot uro ved demens - medisinsk behandling eller kjemisk atferdsregulering?. Tidsskr Nor Lægeforen 2005; 125: 1672-5. PubMed 
74. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43. Journal of the American Medical Association 
75. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer`s disease. N Engl J Med. 2006; 355: 1525-38. PubMed 
76. Douglas IJ, Smeeth L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 2008; 337: a1227. BMJ (DOI) 
77. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35. New England Journal of Medicine 
78. Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. Curr Treat Options Neurol 2016; 18(9): 40. pmid:27476067 PubMed 
79. Cao B, Rosenblat JD, Brietzke E, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer`s disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes Obes Metab. 2018. PMID: 29790638 PubMed 
80. Bentham P, Gray R, Sellwold E, et al. Aspirin in Alzheiemer's disease (AD 2000): a randomised open-label trial. Lancet Neurol 2008; 7: 41-9. PubMed 
81. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease. JAMA 2008; 300: 1774-83. Journal of the American Medical Association 
82. Malouf R, Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst Rev 2008; 8: CD004514. Cochrane (DOI) 
83. Dysken MW, Sano M, Asthana S, et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease. JAMA 2014; 311: 33-44. doi:10.1001/jama.2013.282834 DOI 
84. Farina N, Llewellyn D, Isaac MGEKN, et al. Vitamin E for Alzheimer`s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017; 4: CD002854. PMID: 28418065 PubMed 
85. Roy S, Weinstock JL, Ishino AS, et al.. Association of Cognitive Impairment in Patients on 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitors. J Clin Med Res 2017 Jul; 9(7): 638-649. pmid:28611866 PubMed 
86. Burckhardt M, Herke M, Wustmann T, et al. Omega-3 fatty acids for the treatment of dementia. Cochrane Database Syst Rev 2016 11;4:CD009002 Cochrane (DOI) 
87. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the prevention of cognitive decline and dementia. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD005379. DOI: 10.1002/14651858.CD005379.pub3 DOI 
88. Atri A, Frölich L, Ballard C, et al. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease Three Randomized Clinical Trials. JAMA 2018; 319: 130-42. pmid:29318278 PubMed 
89. Kehoe PG, Turner N, Howden B, et al. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2021. doi:10.1016/S1474-4422(21)00263-5 DOI 
90. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. J Biomed Sci. 2020 Jan 6;27(1):18. doi: 10.1186/s12929-019-0609-7. PMID: 31906949 PubMed 
91. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. PMID: 36449413 PubMed 
92. Graff MJ, Vernooij-Dassen MJ, Thijssen M et al. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ 2006; 333: 1196 201.
93. Guure CB, Ibrahim NA, Adam MB, et al. Impact of Physical Activity on Cognitive Decline, Dementia, and Its Subtypes: Meta-Analysis of Prospective Studies. Biomed Res Int 2017; 9016924: Epub Feb 7. pmid:28271072 PubMed 
94. Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry 2012; 169: 946-53. PMID: 22952073 PubMed 
95. Huntley JD, Gould RL, Liu K, et al. Do cognitive interventions improve general cognition in dementia? A meta-analysis and meta-regression. BMJ Open. 2015 Apr 2;5(4):e005247. doi: 10.1136/bmjopen-2014-005247 DOI 
96. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD005562. DOI: 10.1002/14651858.CD005562.pub2. DOI 
97. Brækhus A. Belastning hos pårørende til pasienter med demenssykdom. DiA, demens i allmennpraksis; 2000: 4.
98. Waldorff FB, Buss DV, Eckermann A, et al. Efficacy of psychosocial intervention in patients with mild Alzheimer`s disease: the multicentre, rater blinded, randomised Danish Alzheimer Intervention Study (DAISY). BMJ 2012; 345: e4693. BMJ (DOI) 
99. Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. BJPsych 2014. doi:10.1192/bjp.bp.113.141119 DOI 
100. Chang YS, Chu H, Yang CY, et al. The efficacy of music therapy for people with dementia: A meta-analysis of randomised controlled trials. J Clin Nurs 2015. doi:10.1111/jocn.12976 DOI 
101. Forrester LT, Maayan N, Orrell M, et al. Aromatherapy for dementia. Cochrane Database of Syst Rev 2014; 2: CD003150. doi:10.1002/14651858.CD003150.pub2 DOI 
102. Helsedirektoratet. Kostrådene og næringsstoffer. Inntak av næringsstoffer. 2.6. Alkohol. www.helsedirektoratet.no 
103. Verghese J, Lipton RB, Katz MJ, et al. Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003; 348: 2508-16. New England Journal of Medicine 
104. Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies. Neurology. 2020 Jun 17:10.1212/WNL.0000000000009816. doi: 10.1212/WNL.0000000000009816. PMID: 32554763. PubMed 
105. Dhana K, Franco OH, Ritz EM, et al. Healthy lifestyle and life expectancy with and without Alzheimer’s dementia: population based cohort study. BMJ 2022; 377: e068390. pmid:35418416 PubMed 
106. Ryan J, Storey E, Murray AM, et al. Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline. Neurology. 2020 Mar 25. pii: WNL.0000000000009277 PMID: 32213642 PubMed 
107. McGuinness B, Craig D, Bullock R, et al. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016 Jan 4;1:CD003160. doi: 10.1002/14651858.CD003160.pub3 DOI 
108. Panegyres PK, Frencham K. Course and causes of suspected dementia in young adults: a longitudinal study. Am J Alzheimers Dis Other Demen 2007; 22(1): 48-56. pmid:17534002 PubMed 
109. Nicastro N, Assal F, Seeck M. From here to epilepsy: the risk of seizure in patients with Alzheimer's disease. Epileptic Disord 2016 Mar; 18(1): 1-12. pmid:26907471 PubMed 
110. Ljøstad U, Myglånd Å. Alzheimer demens. NEL Nevrologi. Sist oppdatert 24.10.2018. nevro.legehandboka.no
111. Peters ME, Schwartz S, Han D, et al. Neuropsychiatric Symptoms as Predictors of Progression to Severe Alzheimer's Dementia and Death: The Cache County Dementia Progression Study. Am J Psychiatry 2015. pmid:25585033 PubMed 
112. Murphy E, Froggatt K, Connolly S, O'Shea E, Sampson EL, Casey D, Devane D. Palliative care interventions in advanced dementia. Cochrane Database Syst Rev. 2016 Dec 2;12(12):CD011513. doi: 10.1002/14651858.CD011513.pub2. Update in: Cochrane Database Syst Rev. 2021 Sep 28;9:CD011513. PMID: 27911489 PubMed